For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Other research and development expense | - | 4,478 | ||
| Personnel research and development costs | - | 20,503 | ||
| Business development | - | 42,902 | ||
| Revenue | 559 | - | ||
| Cost of sales | 215 | 11,810 | ||
| Gross profit | 344 | - | ||
| Segment reporting, other segment item, amount | - | 18,855 | ||
| Research and development costs | 67,753 | - | ||
| General and administrative expenses | 22,344 | 26,884 | ||
| Restructuring charges | 1,324 | - | ||
| Operating loss | -91,077 | - | ||
| Foreign currency (loss)/gain, net | -8,467 | - | ||
| Other income, net | 3,480 | - | ||
| Benefit from r&d credit | 7,463 | - | ||
| Loss before income tax expense | -88,601 | - | ||
| Revenue | - | 43,258 | ||
| Income tax expense | 11 | 845 | ||
| Net loss | -88,612 | -45,309 | ||
| Basic EPS | -0.63 | -0.33 | ||
| Diluted EPS | -0.63 | -0.33 | ||
| Basic Average Shares | 141,694,702 | 138,752,224 | ||
| Diluted Average Shares | 141,694,702 | 138,752,224 | ||
Silence Therapeutics plc (SLN)
Silence Therapeutics plc (SLN)